Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives $700.00 Average Price Target from Brokerages

Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have received an average rating of “Hold” from the three research firms that are presently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold rating. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $700.00.

Several analysts have commented on the stock. StockNews.com assumed coverage on shares of Atara Biotherapeutics in a research report on Wednesday. They set a “hold” rating for the company. HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, May 22nd.

Atara Biotherapeutics Trading Up 13.2 %

NASDAQ:ATRA opened at $8.26 on Friday. Atara Biotherapeutics has a 1 year low of $4.96 and a 1 year high of $63.38. The firm has a 50 day moving average of $14.22 and a 200-day moving average of $16.19. The stock has a market capitalization of $39.81 million, a P/E ratio of -0.16 and a beta of 0.54.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Thursday, May 9th. The biotechnology company reported ($5.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($9.25) by $3.50. Atara Biotherapeutics had a negative net margin of 671.70% and a negative return on equity of 783.31%. The company had revenue of $27.36 million during the quarter, compared to analysts’ expectations of $27.00 million. As a group, analysts forecast that Atara Biotherapeutics will post -15.75 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Anhco Nguyen sold 1,715 shares of the company’s stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $15.50, for a total value of $26,582.50. Following the completion of the transaction, the executive vice president now directly owns 35,939 shares of the company’s stock, valued at approximately $557,054.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CEO Pascal Touchon sold 3,260 shares of the stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $15.50, for a total transaction of $50,530.00. Following the completion of the transaction, the chief executive officer now directly owns 73,165 shares in the company, valued at approximately $1,134,057.50. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Anhco Nguyen sold 1,715 shares of the stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $15.50, for a total transaction of $26,582.50. Following the transaction, the executive vice president now owns 35,939 shares of the company’s stock, valued at $557,054.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 6,120 shares of company stock valued at $94,860. Company insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On Atara Biotherapeutics

A number of large investors have recently modified their holdings of ATRA. Price T Rowe Associates Inc. MD raised its holdings in shares of Atara Biotherapeutics by 8,916.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock valued at $3,442,000 after purchasing an additional 4,903,159 shares during the period. Acadian Asset Management LLC raised its holdings in shares of Atara Biotherapeutics by 49.5% in the 1st quarter. Acadian Asset Management LLC now owns 2,638,687 shares of the biotechnology company’s stock valued at $1,830,000 after purchasing an additional 873,133 shares during the period. Staley Capital Advisers Inc. raised its holdings in shares of Atara Biotherapeutics by 33.3% in the 3rd quarter. Staley Capital Advisers Inc. now owns 1,000,000 shares of the biotechnology company’s stock valued at $1,480,000 after purchasing an additional 250,000 shares during the period. Redmile Group LLC raised its holdings in shares of Atara Biotherapeutics by 3.8% in the 3rd quarter. Redmile Group LLC now owns 6,280,813 shares of the biotechnology company’s stock valued at $9,296,000 after purchasing an additional 232,690 shares during the period. Finally, 683 Capital Management LLC raised its holdings in shares of Atara Biotherapeutics by 20.0% in the 3rd quarter. 683 Capital Management LLC now owns 1,200,000 shares of the biotechnology company’s stock valued at $1,776,000 after purchasing an additional 200,000 shares during the period. 70.90% of the stock is currently owned by institutional investors and hedge funds.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.